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ABSTRACT
Background: Extrahepatic cholestasis that is caused by benign and malignant diseases 
has been reported to increase liver stiffness (LS), as measured by transient elastogra-
phy (TE). 
Objectives:  The  aim  of  this  study  was  to  evaluate  LS  in  patients  with  extrahepatic 
cholestasis due to choledocholithiasis before and after endoscopic sphincterotomy 
and stone removal.
Patients and Methods: LS was measured by TE (Fibroscan) in patients with extrahepatic 
cholestasis that was caused by choledocholithiasis before and 1 month after endoscop-
ic sphincterotomy and successful stone removal.
Results: We studied 12 patients (7 females, 5 males), aged 36 to 76 years (mean age 57.1 
± 11.6 years), with extrahepatic cholestasis that was caused by choledocholithiasis. 
LS was increased in all patients (range: 6.2–18.4 kPa; mean: 8.9 ± 3.5 kPa) before endo-
scopic therapy. Successful biliary drainage was effected by sphincterotomy and stone 
removal in all patients, which led to a significant decline in LS to 3.9–8.1 kPa (Mean: 
5.6 ± 1.2 kPa; p < 0.001) within a mean observation time of 29 days. The decrease in LS 
values correlated significantly with a decline in serum total bilirubin levels (r = 0.691; 
p < 0.0001). 
Conclusions:  Extrahepatic  cholestasis  due  to  choledocholithiasis  increases  LS  and 
should be excluded before assesing liver fibrosis by transient elastography.
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Background
Measuring liver stiffness (LS) by transient elastography 
(TE) is a noninvasive and rapid method for diagnosing 
liver fibrosis in chronic liver diseases. A strong correla-
tion  between  LS  values  and  liver  fibrosis  stage,  as  as-
sessed by liver biopsy, has been reported in chronic hep-
atitis C and other chronic liver diseases (1-6). However, LS 
values can be influenced by other factors, which should 
be taken into account when interpreting such values in 
 Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co  All right reserved.Hepat Mon. 2011;11(5):372-375
373 Liver stiffness in extrahepatic cholestasis Trifan A et al.
assessing liver fibrosis in chronic liver diseases. Thus, ir-
respective of etiology, LS values are influenced by gender, 
body mass index, metabolic syndrome, and biochemical 
flares of hepatitis and cirrhosis (7-13). Recently, extrahe-
patic cholestasis that is caused by benign or malignant 
diseases has also been reported to increase LS, regardless 
of fibrosis (14, 15). 
Objectives
The aim of this study was to assess LS by TE in patients 
with extrahepatic cholestasis that was caused by chole-
docholithiasis before and after endoscopic sphinctero-
tomy and stone removal.
Patients and Methods
Patients
Twelve  patients  with  extrahepatic  cholestasis  due  to 
choledocholithiasis,  referred  to  the  Gastroenterology 
and Hepatology Institute of Iasi, Romania, for therapeu-
tic  endoscopic  retrograde  cholangiopancreatography 
(ERCP) between April 2009 and October 2009, were en-
rolled in this prospective study. The diagnosis of chole-
docholithiasis was established by abdominal ultrasonog-
raphy  or  magnetic  resonance  cholangiography.  Initial 
laboratory tests included measurements of total serum 
bilirubin, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), gamma-glutamyl transferase (GGT), 
and alkaline phosphatase (AP). All patients had jaundice 
(usually mild), but no other signs of chronic liver disease 
(cirrhosis) were present. In all cases, therapeutic ERCP 
was performed, and biliary drainage was re-established 
by sphincterotomy and stone removal. All patients gave 
their informed consent; the study was approved by the 
local ethics committee. 
Measurements
LS  was  measured  by  TE  (Fibroscan,  Echosens,  Paris, 
France) in all patients before and 4 weeks after therapeu-
tic ERCP. Details of the examination have been described 
(16). Results were expressed as the median value of all 
measurements in kilopascals (kPa). The result was reli-
able only when 10 successful shots and a success rate of 
measurement of greater than 60% (ratio between vali-
dated and total measurements) were obtained. In addi-
tion,  the  median  of  all  successful  measurements  was 
considered  representative  of  liver  stiffness  only  if  the 
interquartile range (IQR) of all validated measurements 
was less than 30% of the median value. The normal value 
of LS in our institution is 5.5 ± 1.6 kPa.
Statistical analysis
A  statistical  analysis  was  performed  using  SPSS,  v.  13 
(SPSS  Inc.,  Chicago,  IL,  USA);  results  were  expressed  as 
mean ± standard deviation (SD). All p-values were derived 
from paired t-tests, and a level of < 0.05 was considered 
statistically significant. The correlation between LS value 
and serum bilirubin level was analyzed by Pearson cor-
relation.
Results
Demographics and liver stiffness
The  study  included  12  patients  (7  women,  5  men), 
aged 36 to 76 years (Mean age: 57.1 ± 11.6 years), with ex-
trahepatic  cholestasis  due  to  choledocholithiasis.  The 
patients’ characteristics and LS values before and after 
therapeutic ERCP are summarized in Table 1. The mean in-
terval between LS measurements (before and after ther-
apeutic ERCP) was 29 days (range 27 to 32 days). Before 
therapeutic ERCP, LS was elevated in all patients, ranging 
from 6.2–18.1 kPa (Mean: 8.9 ± 3.5 kPa) (Table 1). Successful 
biliary drainage led to a significant decline in LS to 3.9–8.1 
kPa (Mean: 5.6 ± 1.2 kPa; p < 0.001) within the mean ob-
servation time.
Serum bilirubin
Total serum bilirubin levels (normal: less than 1.1 mg/
dL) elevated in all patients before therapeutic ERCP, rang-
ing from 2.8 to 14.1 mg/dL (mean: 6.5 ± 3.9 mg/dL). After 
endoscopic sphincterotomy and stone removal, serum 
bilirubin fell to 1.7 to 12.5 mg/dL (mean: 5.2 ± 3.6 mg/dL; 
p < 0.0001) (Table 1), which correlated significantly with 
a decline in LS by 0.7 to 10.9 kPa (Mean: 3.3 ± 2.7 kPa) (r = 
0.691; p < 0.0001).
Discussion
This study demonstrates that extrahepatic cholestasis 
due to choledocholithiasis increases LS values, as mea-
sured by TE. We noted increased LS values in all patients 
before therapeutic ERCP and a significant decline in val-
ues  after  successful  biliary  drainage  (sphincterotomy 
and stone removal). Serum total bilirubin values ranged 
between 2.8 to 14.1 mg/dL before therapeutic ERCP and 
decreased to normal values in most patients after endo-
scopic therapy. Until several years ago, liver biopsy was 
the sole method of evaluating hepatic fibrosis and is still 
regarded as the standard assessment of fibrosis in pa-
tients with chronic liver diseases. However, liver biopsy is 
invasive and carries certain unavoidable risks that have 
severe complications (17, 18). In addition, the accuracy 
of liver biopsy in assessing fibrosis has been questioned 
due to intra- and interobserver variability and sampling 
errors (19, 20). These limitations have led to the develop-
ment of noninvasive methods for assessing liver fibrosis. 
TE (Fibroscan) is a new sonography-based, noninvasive, 
and rapid method of diagnosing and quantifying hepat-
ic fibrosis in patients with chronic liver diseases. TE mea-
sures LS, and several studies have documented a strong 
correlation  between  LS  values  and  liver  fibrosis  stage, 
as assessed by liver biopsy in chronic liver diseases (1-6). 
However, LS values can be influenced by several factors. 
Men have significantly higher values than women (7-13), Hepat Mon. 2011;11(5):372-375
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as do patients with metabolic syndrome (11). Further, LS 
values are elevated in subjects with body mass index > 
30 kg/m2 and during alanine aminotransferase flares in 
chronic viral hepatitis (7-10, 12, 13). Recently, extrahepatic 
cholestasis that is caused by benign and malignant dis-
eases was reported to increase LS, regardless of fibrosis 
(14, 15). Because TE has gained in popularity over the past 
several years and is now used widely in clinical practice, 
these conditions should be considered when interpret-
ing LS values in assessing hepatic fibrosis in chronic liver 
diseases.
Our  results  confirm  those  of  Millonig  et  al.  (15)  and 
Harata et al. (14). Millonig et al. (15) observed increased LS 
values in patients with extrahepatic cholestasis, primar-
ily due to malignant invasion of the biliary tree; success-
ful biliary drainage led to a significant decrease in LS val-
ues, which correlated with bilirubin levels but not with 
ALT, AST, or GGT levels. Harata et al. (14) measured LS by TE 
in 29 patients with extrahepatic cholestasis and reported 
increased LS values that suggested liver cirrhosis, which 
correlated  positively  with  serum  total  bilirubin  levels 
and negatively with serum ALT and AST levels; a reduc-
tion in bilirubin levels after therapeutic biliary drainage 
significantly correlated with decreased LS. 
The mechanisms by which high LS develops in extra-
hepatic cholestasis remain unknown, but increased hy-
drostatic pressure due to impaired bile flow appears to 
contributed to is, as demonstrated by Millonig et al. (15) 
by experimental bile duct ligation in pigs for 120 min-
utes, during which LS values increased significantly and 
decreased rapidly within 30 minutes after restoration of 
bile flow. Nevertheless, the mechanism of increased LS in 
extrahepatic cholestasis differs from that in acute hepati-
tis, in which increased LS values correlate with ALT levels 
(7, 8, 10, 13).
There are several limitations of our study that require 
consideration. First, the number of patients who were 
studied was small and included only those with extrahe-
patic cholestasis that was caused by choledocholithiasis. 
Further, the correlation between LS values and other bio-
chemical parameters (ALT, AST, GGT, AP), except serum 
total bilirubin, was analyzed. Also, we did not determine 
whether LS values corresponded to the histological ex-
tent of fibrosis after resolution of extrahepatic cholesta-
sis, because liver biopsy was not included in the study 
protocol.
Knowledge of the presence and severity of hepatic fi-
brosis is important from the diagnosis and prognosis of 
patients with chronic liver diseases. TE measurements 
significantly overestimate the stage of liver fibrosis in 
patients with extrahepatic cholestasis that is caused by 
choledocholithiasis and other benign and malignant dis-
eases; thus, this condition should be added to the list of 
those that are already known to influence LS values (gen-
der, body mass index, metabolic syndrome, ALT flares in 
hepatitis and cirrhosis).
Extrahepatic  cholestasis  that  is  caused  by  choledo-
cholithiasis  increases  LS  values,  which  correlate  with 
serum total bilirubin levels. Significant reductions in LS 
and bilirubin levels are obtained after successful endo-
scopic sphincterotomy and stone removal. An important 
prerequisite for the interpretation of LS values is to ex-
clude extrahepatic cholestasis in patients who are under-
going TE for the diagnosis of liver fibrosis in chronic liver 
diseases. 
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